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Abstract
The lung is among the deadliest sites of breast cancer metastasis. Previous work from our
laboratory demonstrated that aggressive CD44-expressing breast cancer cells preferentially
metastasize to the lung in vivo, and observed the presence of multiple CD44-interacting
proteins in the lung including E-, L- and P-selectin. We hypothesized that lung-derived
selectins promote breast cancer migration and/or growth via interactions with CD44. Using an
ex vivo model of the soluble lung-microenvironment, we demonstrate that lung-derived
selectins enhance in vitro migration but not proliferation of breast cancer cells. Coimmunoprecipitation experiments reveal that CD44 expressed by breast cancer cells in vitro
interacts with soluble selectins. The mechanism underlying the pro-migratory effect of lungderived selectins is independent of ezrin/radixin/moesin (ERM) or CREB phosphorylation.
Future studies should be aimed at elucidating mechanisms by which lung-derived selectins
exert their pro-migratory function and whether these proteins can be targeted therapeutically
to reduce lung metastasis of breast cancer.
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1

INTRODUCTION

1.1

Cancer
Cancer is a family of diseases hallmarked by uncontrolled cell growth and

proliferation. This dysregulation often occurs as a result of normal cells accumulating
multiple genetic mutations over time1. Mutations relevant to cancer development often
occur in either oncogenes or tumour suppressor genes. Oncogenes are genes that when
activated through gain-of-function mutations will promote cancer cell growth and
division2. In contrast, tumour suppressor genes are negative regulators of cell growth and
overall malignancy; their inactivation through loss-of-function mutations leads to
increased cell proliferation and survival. As cancers progress, the cells gain the
characteristic abilities to self-sustain proliferative signaling, replicate infinitely, resist cell
death, induce angiogenesis, activate metastasis and avoid destruction by the immune
system3. A mass of these cancerous cells is referred to as a tumour, which can be either
benign or malignant in nature.4 Benign tumours remain confined to their original location
and are usually non-life-threatening. In contrast, a malignant tumour can invade
surrounding tissue and also spread to distant regions of the body; these are life-threatening.

1.2

Breast Tissue and Breast Cancer
The principal structure of the breast is the mammary gland5. It is composed of milk-

producing cuboidal epithelial cell-lined acini organized into lobules, with each having a
lactiferous duct responsible for transporting the milk to the nipple for ejection. Breast
cancer is any primary tumour formation originating from the breast tissue, most commonly
the milk-producing lobules and the ducts which transport it6. These structures are
susceptible to cancerous transformation in part because of the cycling stimulation of
estrogen and progesterone on the proliferation of breast epithelial cells7. Over time, this
leads to increased cell turnover and accumulation of genetic defects8.
There are multiple schemas by which breast cancer can be classified, one of which
is based on histopathology. This takes into consideration the structure from which the
tumour cells originated and whether they have remained confined to their site of origin, i.e.
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have not invaded into the surrounding tissue structures. Primary breast tumours which
originate from the lobules and are confined to their site of origin are classified as lobular
carcinoma in situ9. Those originating from the ductal epithelium and have not invaded into
surrounding tissue are classified as ductal carcinoma in situ. At the in situ stage, the
tumours are non-invasive and can be effectively treated with surgery, hormone therapy
and/or radiation therapy. The five-year survival rate for affected patients is 98.6%10.
However, once the cancer has become invasive and has begun infiltrating the surrounding
tissue, the prognosis worsens. If the invasion is allowed to persist, breast cancer can spread,
or metastasize, to distant organs.
An additional and more detailed system used to stratify breast cancer cases is based
on molecular subtype. Cases can be categorized into one of four groups: luminal A, luminal
B, HER2-enriched and basal-like (triple-negative; TN). Grouping into each group is based
on the combination of their hormone receptor status (estrogen [ER] and progesterone [PR]),
HER2 (human epidermal growth factor receptor 2) status and proliferation index (Ki-67).
Luminal A is the most commonly diagnosed subtype of breast cancer and is characterized
by ER+/PR+/HER2- and a low rate of proliferation11. Diagnosed patients show good
prognosis and survival rates as they respond well to hormone therapy. Luminal B is a more
aggressive phenotype than luminal A and is identified based on an ER+/PR+ phenotype
with either a high proliferation rate and/or HER2+ status. Survival rates are slightly lower
than those observed in luminal A breast cancer patients, but still fairly high as these patients
also respond well to hormone therapy. HER2-enriched tumours are hormone receptor
negative (ER-/PR-) and HER2+. Generally, these tumours are associated with a poorer
prognosis and higher incidence of metastasis relative to the luminal A/B subtypes12. These
patients are treated with HER2-targeting agents such as Herceptin (trastuzumab) that can
directly interfere with HER2 receptor signaling and subsequently reduce cancer cell growth
and tumour progression13. The only subtype for which no targeted therapies currently exist
is basal-like/TN, which are characterized by an ER-/PR-/HER2- status and are highly
aggressive in nature. The average expected 5-year survival rate for these patients is
approximately 26%, as TN breast tumours commonly metastasize to essential
physiological organs, such as the lung10, 14.
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1.3

Metastasis
Metastasis is a complex process through which secondary tumours in distant organ

sites can occur7. The metastatic cascade (Figure 1) can initiate once the primary tumour
has developed its own blood supply through angiogenesis to support its metabolic
demands8. Not only do these newly formed blood vessels increase the growth potential of
the primary tumour, but they also create a means through which cancer cells can spread to
other organs. The first step of the metastatic cascade is intravasation, a process by which
tumour cells that have dissociated from the solid tumour will cross the endothelium and
enter the blood circulatory system15. Tumour cells can enter the circulatory system directly
or indirectly via the lymphatic system. Once in circulation, tumour cells must survive the
shear stress of blood flow and evade destruction by immune cells before they can arrest in
the capillary beds of distant organs. At these sites, tumour cells must extravasate in order
to exit the circulatory system and enter the secondary organ. These tumour cells will only
establish a metastatic tumour if they are able to survive and proliferate in the organ's
microenvironment.
In the metastatic breast cancer setting, current therapies are largely ineffective and
5-year survival rates are approximately 26%6, 7. The majority of breast cancer-related
deaths can be attributed to metastasis, as tumours in the brain, lung, liver and bone can
impair essential physiological functions and eventually lead to death16. In comparison,
primary tumours when contained within the breast are non-life threatening. For example,
patients with metastatic tumours in the lung present clinically with pain, hemoptysis,
pleural effusions and/or pulmonary dysfunction17. A pleural effusion is the build-up of fluid
in the pleural space around the lungs and can negatively affect breathing and gas
exchange18, 19. Unfortunately, pleural effusions caused by a malignancy are incurable and
treatments are focused on palliative care. The median survival from clinical recognition of
a malignant pleural effusion is 4 months20. The high mortality associated with metastasis
therefore presents an important, clinically-relevant problem requiring further research to
resolve.
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Figure 1. The metastatic cascade. Tumour cells that have dissociated from the primary
tumour have the potential to spread to distant organs. This occurs through four key steps,
which begins with intravasation. Intravasation is the process by which cells traverse the
endothelium and enter the systemic circulation. These cells then circulate throughout the
body until they reach a location where they will exit the circulation and enter the organ’s
parenchyma. This step is known as extravasation. If the organ microenvironment possesses
ideal conditions for growth of the tumour cells, they may grow and proliferate to form
secondary metastatic tumours.
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1.4

Metastatic Organ Tropism
Clinically, it has been previously observed that breast cancer metastasizes most

often to the lung, bone, liver, brain and lymph nodes21. This phenomenon of preferential
metastasis to specific organs has been observed in different types of cancer and is termed
organ tropism22. The two main theories that have been proposed to explain organ tropism
are Stephen Paget’s “seed and soil” hypothesis and James Ewing’s mechanical arrest
theory21. In 1889, Paget hypothesized that organ-specific patterns of metastasis were a
result of cancer cells (“seeds”) requiring specific organ microenvironmental conditions at
secondary sites (“soil”) to be able to survive and grow23. This was proposed based on his
observation of a non-random pattern of metastasis to specific visceral organs and bone
from the autopsy records of 735 female breast cancer patients. James Ewing proposed an
alternative theory forty years later, postulating that organ tropism could be accounted for
by blood flow patterns14. Specifically, his theory emphasized that cancer cells would
mechanically arrest in the first capillary bed they encountered. However, his theory could
not explain why some organs that are served by only a small fraction of the blood flow
(e.g. brain and bone) are disproportionately more affected by metastasis, while other organs
that receive considerable blood flow (e.g. heart) are uncommonly involved in the
colonization of secondary tumours24.
It is likely that these two theories operate in concert to allow tumour cells to reach
secondary organ sites and form metastases. Based on these theories, using the lung as an
example, breast cancer cells that have dissociated from the primary tumour and invaded
nearby capillaries would be carried within venous blood to the heart and then circulated to
the lungs, where tumour cells would mechanically arrest in the first capillary bed they
encounter in the lungs. Secondary tumour formation could then occur; but would be
dependent on compatible characteristics of the breast cancer cells (the “seed”) and
supporting factors produced by the lung microenvironment (the “soil”)25.

1.4.1

The “Seed” – Breast Cancer Cells
Studies carried out by Joan Massagué’s group have demonstrated the influence of

breast cancer cell gene expression profiles on organ-specific metastasis. Using three
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different models of metastasis and multiple rounds of in vivo selection, they generated
brain-seeking26, bone-seeking27 and lung-seeking28 variants of the aggressive TN human
breast cancer cell line MDA-MB-231. Transcriptome analysis demonstrated that each
variant had a unique gene expression profile. When the data from the lung-seeking variant
was compared against patient breast tumour samples and patient incidences of lung
metastasis, it was found that the expression pattern of 18 univariately significant genes was
enough to define a lung metastasis signature (Table 1)28. In further studies, this signature
was shown to be associated with breast cancer relapse to the lung, but not to the bones,
liver or lymph nodes26, 29. There was a weak association of the lung metastasis signature
with relapse to the brain, likely because six of the 18 genes are also found in the brain
metastasis signature26. These genes comprising the lung metastasis signature encode for a
variety of different protein classes; including extracellular receptors, adhesion receptors,
chemokines, secreted proteases and transcriptional regulator proteins28. Overall, their
findings highlight the relationship between breast cancer cells, their genetic signature and
the organ microenvironments to which they preferentially metastasize. However, there are
other characteristics that have used to define a subset of cancer cells with an overall
increased ability for metastasis.

1.4.1.1

“Stem-Like” Breast Cancer Cells

Cancer stem cells (CSCs) represent a small subpopulation of cancer cells found
within solid tumours, and they have an increased ability for both primary tumour formation
and metastasis30, 31. Their existence was first validated by John Dick and colleagues in 1997
based on findings in human acute myeloid leukemia that only a subset of cells was capable
of inducing leukemia32. CSCs are defined as cells that have both the ability to self-renew
and give rise to a wide range of differentiated cells that comprise a tumour33. In the context
of breast cancer, CSCs were first isolated based on a CD44+/CD24- phenotype34. As few as
100 CD44+/CD24- cells when injected into the mammary fat pad of mice were able to form
tumours. This contrasts with other phenotypes, where as many as 10,000 cells when
injected into the mammary fat pad were unable to form tumours. Breast cancer stem cells
have since then been further defined to include high activity of the aldehyde dehydrogenase
1 (ALDH1)35. This intracellular enzyme oxidizes aldehydes to protect stem cells and its
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Table 1. Breast cancer lung metastasis signature

Symbol

Gene Name

Also found in
brain metastasis
signature26

ANGPTL4

Angiopoietin-like 4

+

FSCN1

Fascin homologue 1, actin-bundling protein
(Strongylocentrotus purpuratus)

+

LTBP1

Latent transforming growth factor beta binding protein 1

+

MMP1

Matrix metalloproteinase 1 (interstitial collagenase)

+

PTGS2

Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase)

+

RARRES3

Retinoic acid receptor responder (tazarotene induced) 3

+

C10orf116

Chromosome 10 open reading frame 116

–

CXCL1

Chemokine (C-X-C motif) ligand 1 (melanoma growthstimulating activity, alpha)

–

CXCR4

Chemokine (C-X-C motif) receptor 4

–

EREG

Epiregulin

–

ID1

Inhibitor of DNA binding 1, dominant-negative helix–loop–
helix protein

–

KRTHB1

Keratin, hair, basic, 1

–

KYNU

Kynureninase (L-kynurenine hydrolase)

–

LY6E

Lymphocyte antigen 6 complex, locus E

–

MAN1A1

Mannosidase, alpha, class 1A, member 1

–

NEDD9

Neural precursor cell expressed, developmentally
downregulated 9

–

TNC

Tenascin C (hexabrachion)

–

VCAM1

Vascular cell adhesion molecule 1

–

Adapted from Minn, A. J. et al, Nature 2005, 436 (7050), 518-2428
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activity is also associated with early stem cell differentiation36, 37. Functionally, it has been
shown that if cells are isolated based on an ALDHhi/CD44+/CD24- phenotype, as few as 20
cells transplanted into a mammary fat pad could generate a tumour35. Previous studies by
our laboratory provided the first evidence of the ALDHhi/CD44+/CD24- breast cancer cell
subpopulation as metastasis-initiating cells38. In vitro, these cells demonstrated increased
growth, adhesion, colony formation, migration and invasion relative to their
ALDHlowCD44low counterparts. They also demonstrated that ALDHhi/CD44+/CD24human breast cancer cells are both more tumorigenic and metastatic in vivo than
ALDHlowCD44- cells, with a particular propensity to metastasize to the lung. Together with
Massagué’s observations, these studies highlight the existence of properties intrinsic to
certain breast cancer cells (the “seeds”) that enhance their metastatic ability to different
organ sites. In particular, the role that CD44 may play in enhancing the abilities of
ALDHhiCD44+ breast cancer cells to interact with their microenvironment during
metastasis may relate to its function as a cell surface receptor.

1.4.1.2

Cluster of Differentiation 44 (CD44) Receptor

The cluster of differentiation 44 receptor (CD44), belongs to a family of cell
adhesion molecules with well-established functions in mediating cell-cell and cellextracellular matrix (ECM) adhesion and communication39. There are over 20 different
isoforms of this transmembrane receptor, and they vary from 80-200 kDa in size. This
variance in size is generated from differences in RNA splicing and post-translational
protein modifications40. CD44 is encoded by a 20 exon-containing gene. Eight of the exons
are constant and found in all isoforms, while others are inserted in variants. Inclusion of
additional exons lengthens the amino-terminal extracellular region of the receptor and
exposes new binding sites for both posttranslational modifications and ligand binding41.
The cytoplasmic C-terminal region of the receptor does not differ between variants and
plays an important role in receptor signal transduction42, 43. Studies have shown that CD44
is involved in the regulation of cell growth, differentiation, survival and motility44. Some
of these processes are regulated by CD44 at the transcriptional level as the intracellular
domain of CD44 can be cleaved to release a fragment capable of acting as a transcriptional
factor45. Others such as motility have been shown to be regulated at least in part through
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interactions of CD44 with members of the Band 4.1 superfamily of proteins, including
ezrin, radixin and moesin (ERM)46. ERM proteins allow CD44 to exert its influence on cell
shape and migration by crosslinking the actin cytoskeleton to CD44. The affinity of ERM
proteins for CD44 is dependent on their phosphorylation status at key tyrosine and
threonine residues. The phosphorylation is mediated by either growth factor receptors such
as MET47, a receptor tyrosine kinase, or downstream proteins such as protein kinase Cα48.
Under normal conditions, CD44 is widely distributed and its expression has been
observed in the epithelial tissue of many different organs, including but not limited to lung,
liver, bone marrow, mammary gland and kidneys49. The actions of CD44 in each tissue are
likely related to the isoforms of the receptor present and ligands present, as not all variants
have the same affinity for CD44 ligands. CD44 ligands that have previously been identified
include hyaluronan50, osteopontin51, serglycin52, E-, L- and P-selectin53-55. The standard
isoform (CD44S) has been shown to be important in the context of breast cancer. It has
specifically been shown to be involved in breast cancer cell adhesion, migration and
invasion, and is the isoform utilized in isolation and functional analysis of stem-like breast
cancer cells based on either the CD44+/CD24- or ALDHhi/CD44+/CD24- phenotype56, 57.

1.4.2

The “Soil” – Organ Microenvironments
The influence of organ microenvironments (the “soil”) on tumour growth and

metastasis has been previously reported based on clinical observations of cancer patients,
in vitro experiments, and experimental murine models of cancer58,

59

. These studies

illustrate that metastasis is often largely independent of an organ's vascular anatomy, blood
flow or the number of tumour cells delivered to an organ site. Instead, the potential for
successful secondary tumour formation and growth is heavily dependent on the interactions
between organ microenvironments and tumour cells.
The role of the soluble organ microenvironment in promoting breast cancer
metastatic behavior has been previously examined by our lab25, 60-62. We developed an ex
vivo model system to study the influence of organ-derived soluble factors on breast cancer
cell migration and proliferation. The specific organs that were examined represented the
five most common clinical sites of breast cancer metastasis, including lung, bone, liver,
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brain and lymph nodes. These different organs were aseptically harvested from female
nude athymic mice and cultured to generate organ conditioned media (CM). Using this
model, Chu and colleagues demonstrated that human breast cancer cells exhibit cell linespecific and organ-specific chemotactic and proliferative patterns that reflect their in vivo
patterns of metastasis25. Notably, all 4 cell lines showed increased migration towards lungconditioned media relative to basal media, and 2 of the 4 cell lines showed increased
proliferation in lung-conditioned media. This suggested that specific soluble factors within
the lung microenvironment may be promoting the metastatic behaviour of breast cancer
cells. Using a protein array, Chu identified 70 different soluble proteins that were found in
the lung-CM. Many of these factors had been previously implicated in metastasis,
including 5 CD44 ligands (osteopontin, basic fibroblast factor, and E-, L-, and P-selectin)
as well as proteins/pathways such as epiregulin (EREG), OPN, and urokinase-type
plasminogen activator (uPA) that had been previously associated with lung metastasis of
breast cancer by Massagué’s group25, 28. The focus of this thesis is to further investigate the
role of lung-derived E-, L-, and P-selectin in breast cancer metastatic behaviour.

1.5

Selectins
The selectins are a three-member family of type I cell-surface glycoproteins that

function to mediate adhesions between leukocytes, platelets and the endothelium63.
Structurally, selectins consist of a N-terminal lectin domain, followed by an epidermal
growth factor domain, two to nine consensus repeats (two in L-selectin, six in E-selectin
and nine in P-selectin), a transmembrane domain and a C-terminal cytoplasmic domain
(Figure 2A)64. There is high sequence homology between E-, L- and P-selectin in all
domains except the transmembrane and cytoplasmic domains. The lectin domain
recognizes specific carbohydrates on target proteins to which selectins bind.
Selectins differ in terms of their expression. L-selectin is constitutively expressed
on the surface of most leukocytes65. P-selectin is stored intracellularly in granules in
platelets and endothelial cells until the cell is activated by pro-inflammatory stimuli, after
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Figure 2. Membrane-bound selectins and the generation of their soluble forms. A)
The general structure of selectin proteins consists of a N-terminal lectin domain, an
epidermal growth factor (EGF) domain, followed by 2-9 consensus repeats, a
transmembrane domain and a C-terminal cytoplasmic domain. B) Soluble forms of each
selectin are generated through proteolytic cleavage from the cell surface. i) E-selectin is
expressed on endothelial cells and is cleaved by an unknown mechanism into soluble Eselectin. ii) P-selectin is expressed on the surface of both endothelial cells and platelets. Its
cleavage from the cell surface is mediated by tumor necrosis factor alpha converting
enzyme. iii) L-selectin is expressed on the surface of leukocytes and its cleavage is
mediated by matrix metalloproteinase 9.
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which P-selectin is rapidly translocated to the cell surface66. E-selectin is only expressed
on the surface of activated endothelial cells. Its expression is increased hours after cell
stimulation with pro-inflammatory mediators as E-selectin is not stored intracellularly in
granules, rather it is produced de novo63, 67
Selectins exist not only as membrane bound proteins but also as cleaved soluble
proteins. Cleavage is likely proximal to the membrane spanning domain as it has been
noted that there is a slight difference in molecular weight between the membrane-bound
and soluble forms (Figure 2B)68-70. In vitro studies suggest that soluble E-, L- and Pselectin remain functionally active after having been shed from the cell surface71-73. Lselectin and P-selectin cleavage occurs following cell activation, and the proteases
responsible for generating the soluble forms include TNF-alpha converting enzyme and
matrix metalloproteinase 9 (MMP-9), respectively65, 74. With respect to E-selectin, the
protease responsible for generating the soluble form has not yet been identified. However,
it is known that E-selectin is shed from the cell surface under normal conditions and that
the rate of E-selectin cleavage is increased following stimulation of endothelial cells by
cytokines70.

1.5.1

Clinical Relevance of Selectins in Cancer
Of the three selectins, E-selectin is the most well-studied in the context of cancer.

It has been clinically observed that the serum levels of E-selectin are significantly higher
in patients with advanced breast cancer that have distant metastasis when compared to
either earlier stage patients with localized primary breast tumors or those who have
completed initial treatment and have no evidence of relapse at one year post-diagnosis75-77.
Similarly, other studies have demonstrated that high E-selectin serum concentrations in
patients with breast cancer are prognostic for reduced progression-free and overall survival
relative to those with low serum concentrations of E-selectin77, 78. In addition to these
prognostic studies of serum E-selectin, others have examined the effect of E-selectin
polymorphisms on breast cancer prognosis. They observed that a genetic mutation resulting
in the substitution of serine 128 by arginine increases the affinity of E-selectin for its
binding partners79. Clinically, patients homozygous for this mutation have poorer survival
than patients who are homozygous for the wild-type allele80.

13

For L-selectin, it has not been reported in the literature whether levels of the protein
in the blood are affected by breast cancer. However, in acute myeloid leukemia, one study
noted that patients with elevated plasma L-selectin levels (defined as a value three standard
deviations above the average of healthy control individuals) had lower probabilities of
achieving complete cancer remission and had reduced progression-free and overall
survival81. In another study that examined patients with high-grade muscle invasive
bladder cancer, higher concentrations of L-selectin were found in the serum of patients
with metastatic vs. nonmetastatic stages of the disease82. Similarly, soluble P-selectin has
been detected in increased amounts in the sera of breast cancer and colon cancer relative
to healthy controls, however no significant differences were noted in P-selectin
concentrations between stages of each cancer83, 84. Although a mechanistic understanding
of selectins in the clinical setting of breast cancer is somewhat limited, studies using
experimental models have provided more detailed evidence of the functional importance
of selectins in cancer.

1.5.2

Experimental Evidence of the Role of Selectins in Metastasis
Animal models to represent the deficiency of one or more selectins have previously

been generated through gene knockout. Phenotypically, selectin deficiencies in single
selectins do not cause infertility or embryonic lethality. However, certain combinations of
deficiencies can cause health issues. Mice deficient in both E- and P-selectin (EP-/-) or E-,
L- and P-selectin (ELP-/-) were more likely to develop mucocutaneous infections that
eventually lead to death. This may be caused by alterations in leukocyte homeostasis and
recruitment, as supported by Robinson and colleagues. They demonstrated that peripheral
blood leukocyte levels were significantly elevated in EP-/- (1.7 fold relative to wild-type)
and ELP-/- mice (2.4 fold), and to a lower extent in mice deficient in P- and L-selectin (PL/-

) (1.2 fold)85. This leukocytosis was likely caused by impairments of leukocyte

recruitment to sites of inflammation and infection, as they also demonstrated that
neutrophil influx in EP-/-, PL-/- and ELP-/- mice to sites of chemically-induced peritonitis
was less than one-third of that observed in wild-type mice.
While these deficiencies may negatively affect immune cell recruitment, evidence
suggests that they may also be advantageous to disruption of metastasis. In an experimental
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model of spontaneous breast cancer metastasis, the number of lung metastasis foci was
significantly lower in E-/- and EP-/- mice than wild-type86. Similar studies have been
conducted to examine the influence of L- and P-selectin single or double knockout on lung
metastasis in other tumour types including colon carcinoma. P-/- mice and L-/- mice
demonstrated lower lung metastatic burden relative to the wild-type control87. Relative to
the single-knockout mice, the lung metastatic burden was significantly lower in PL-/- mice,
suggesting a synergistic effect.
Our lab has previously identified the presence of L-,E, and P-selectin in lung
conditioned media. Chu and Xia et al examined the effect of depleting L-selectin from
lung-conditioned media on breast cancer cell migration and proliferation. They observed
that L-selectin was not involved in cell proliferation of TN breast cancer cells but did affect
cell migration/ invasion25. However, the role of E- and P-selectin in mediating breast cancer
metastatic behavior as well as the mechanisms by which this may occur require further
investigation, and that is the overall focus of this thesis.

2

STUDY RATIONALE
Breast cancer is the leading cancer diagnosis and second leading cause of cancer-

related death among Canadian women. Current therapies are highly effective in treating
breast cancer localized to the breast. However, these therapies are largely ineffective in the
metastatic setting, and metastasis accounts for the majority of breast cancer patient deaths.
Previous studies from our lab and others have demonstrated that breast cancer cells which
express high levels of CD44 are metastatic and preferentially spread to the lung. In
accordance with Paget’s “seed and soil” hypothesis, we previously sought to understand
whether there were factors present in the lung that may interact with CD44 + breast cancer
cells to promote lung metastasis, and observed that E-, L- and P-selectins, known ligands
of CD44, were present in lung-conditioned media. In addition, previous animal studies that
involved either breast cancer or colon cancer have demonstrated that deficiency or
inhibition of each selectin independently significantly reduced the extent of lung
metastasis. However, it is currently unclear whether E-, L-, and/or P-selectins specifically
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derived from the lungs influence breast cancer cell metastatic behaviour, and if so, whether
they do so through interactions with CD44.

HYPOTHESIS

3

Lung-derived selectins promote breast cancer migration and/or growth via
interactions with CD44.

SPECIFIC AIMS

4

1. To determine the functional role of lung-derived selectins on breast cancer cell
migration and/ or growth in vitro.
2. To investigate the mechanism(s) by which lung-derived selectins influence breast
cancer cell migration and/ or growth in vitro.

5

MATERIALS & METHODS

5.1

Cell Culture
MDA-MB-231 (ATCC, Manassas, VA) human breast cancer cells were maintained

in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) media
(Invitrogen, Burlington, ON) + 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis,
MO). At 90% confluency, cells were passaged using 1 mM ethylene diamine tetraacetic
acid (EDTA; Bioshop Canada Inc., Burlington, ON). SUM149 (Asterand Inc., Detroit, MI)
were maintained in HAM’S F-12 media (Invitrogen) supplemented with 5% FBS (SigmaAldrich), 5 𝜇g/mL insulin (Invitrogen), 1 𝜇g/mL hydrocortisone (Invitrogen) and 10 mM
HEPES (Invitrogen). At 80% confluency, cells were passaged using 0.25% trypsin/EDTA
in citrate saline (Life Technologies, Carlsbad, CA). Primary pulmonary mouse endothelial
cells (generously provided by Dr. Sean Gill) were maintained in DMEM low
glucose/pyruvate/L-Glutamine media (Thermo Fisher Scientific, Waltham, MA)
supplemented with 18% heat-inactivated FBS (Sigma-Aldrich), penicillin-streptomycin
(50 U/mL penicillin-50 𝜇g/mL streptomycin; Invitrogen) and HEPES (Invitrogen). Cells
were cultured and maintained at 37°C and 5% CO2.
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5.2
5.2.1

Lung-Conditioned Media
Animal and Lung Harvesting
Athymic nude mice were purchased and maintained under the guidelines of the

Canadian Council of Animal care as outlined by the protocol approved by the University
of Western Ontario Council on Animal Care (Appendix 1). Healthy 5-7 week old female
athymic nude mice were euthanized by CO2 inhalation and their lungs and heart were
aseptically removed en bloc. The heart was then carefully removed to avoid damaging the
lungs and discarded, after which the lungs were placed in a pre-weighed 50 mL conical
tube containing 30 mL of PBS.

5.2.2

Lung-Conditioned Media Generation
Following the harvesting of lungs (n=4 mice per session), the total weight of lungs

+ PBS was determined using an electronic balance. Harvested lungs were washed three
times in ice cold PBS before being minced into ~1 mm3 fragments. Lungs were weightnormalized by re-suspension in a 4:1 media to tissue (v/w) ratio in DMEM:F12
supplemented with Mito+ serum extender (1X; BD Biosciences, Mississauga, ON; basal
media) and penicillin-streptomycin (50 U/mL penicillin-50 𝜇g/mL streptomycin;
Invitrogen). Lung fragment/media suspensions were then incubated at 37°C and 5% CO2
for 24 hours. Following incubation, conditioned media (CM) was further diluted four-fold
in basal media, then separated from lung fragments by centrifugation at 900 g for 15 min
at 4°C. Lung-CM was then filtered through a 0.22 𝜇m filter (Corning Inc., Corning, NY),
aliquoted and stored at -80°C until use (Figure 3A). The original protocol for this model
was described by Chu and colleagues21.

5.2.3

Assessment of E-selectin, L-selectin and P-selectin Concentration
To assess the presence and concentration of selectins in lung-CM, Quantikine®

Mouse E-Selectin/CD26E, Quantikine® Mouse sP-selectin/CD62P, and Thermo Scientific
Mouse L-selectin ELISA kits (R&D Systems, Minneapolis, MN, USA) were used. Basal
media, lung-CM, and lung-CM depleted of E, L- or P-selectin (described below and in
Figure 3B) were added to the supplied pre-coated microplates and the ELISAs were carried
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Figure 3. Lung conditioned media generation and selectin immunodepletion. (A)
Healthy female nude mice were euthanized by CO2 inhalation and their lungs removed
aseptically. Harvested lungs were then washed, minced into ~1 mm3 fragments, and
resuspended in a 4:1 media to tissue (v/w) ratio for incubation at 37°C and 5% CO2 for 24
h. Following incubation, heterogeneous solution is further diluted by three volumes of
media, centrifuged and lung-CM filtered prior to use. (B) Immunodepletion of E-, P-, or
L-selectin from lung-CM is accomplished using magnetic Protein-G Dynabeads®. I. An
antibody specific to one type of selectin (E, P, L) bound to G-protein coupled Dynabeads®
was added to lung-CM. II. Lung-CM/antibody-Dynabeads® mixture was mixed for 30 min
to allow antibodies to bind their protein target present in lung-CM. III. After mixing, a
magnet is used to separate lung-CM from the selectin antibody/Dynabeads® complexes. IV.
The remaining lung-CM that is now depleted of the targeted protein is transferred to a
separate tube, filtered through a 0.22 µm syringe filter and stored at -80°C until use.
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out according to the manufacturer's instructions to measure the concentration of E-, L- and
P-selectin in lung-CM and the efficiency of immunodepletion. A four-parameter logistic
(4-PL) standard curve was generated for each experiment using GraphPad Prism 6.0
(GraphPad Software, San Diego, CA) and used to determine the exact protein
concentration in each sample.

5.2.4

Selectin Immunodepletion from Lung-Conditioned Media
To determine the influence of lung-derived selectins on in vitro migration and

proliferation of breast cancer cells, E-, L- and P-selectin were individually immunodepleted
from lung-CM using Dynabeads® Protein G (Life Technologies). Dynabeads were
suspended in 200 𝜇L of wash buffer (PBS + 0.02% Tween-20) to equilibrate and then
placed again on the magnetic rack for 2 min for separation from solution. Wash buffer was
carefully removed and replaced with wash buffer + appropriate antibody.
For E-selectin depletion, 20 𝜇L (0.6 𝜇g) of beads and 4 𝜇L of monoclonal E-selectin
antibody (0.5 mg/mL; R&D Systems) were used per 1 mL of lung-CM. For L-selectin
depletion, 10 𝜇L (0.3 𝜇g) of beads and 8 𝜇L of monoclonal L-selectin (0.5 mg/mL; R&D
Systems) antibody were used per 1 ml of lung-CM. For P-selectin depletion, 30 𝜇L (0.9
𝜇g) of beads and 50 𝜇L of polyclonal P-selectin antibody (0.2 mg/mL; R&D Systems) were
used per 1 ml of lung-CM.
The bead/antibody mixtures were first mixed by pipetting and then allowed to
nutate for 20 min at RT. Following nutation, tubes were placed on the magnetic rack for 2
min to separate antibody-bound beads from solution. The supernatant was carefully
removed, and the antibody-bound beads were washed three times, before the beads were
exposed to 1 mL of lung-CM. The antibody-bound bead and lung-CM mixture were then
nutated for 30 min at RT. Post-nutation, samples were put on the magnetic rack for 2 min
to separate the selectin/antibody/bead complexes from the now depleted lung-CM. A small
aliquot of depleted lung-CM was stored for quantification of protein levels by ELISA and
the rest was transferred to a new tube, passed through a 0.22 𝜇m syringe filter and stored
at -80°C until use (Figure 3B). The selectin/antibody/bead complexes were washed in
wash buffer and magnetically separated from solution three times. Selectin/antibody/bead
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complexes were then suspended in 30 𝜇L of 1x Laemmli buffer and heated at 100℃ in a
water bath for 5 min. Post-heating, samples were magnetically separated from beads, the
supernatant was transferred to a clean tube and used for SDS-PAGE and immunoblotting.
For rescue experiments, an amount of recombinant E-,L, or P-selectin protein that was
equal to the calculated average concentration of each immunodepleted selectin was added
back to depleted lung-CM (E-selectin [0.25 ng/mL], L-selectin [7.05 ng/mL]) and Pselectin [10.39 ng/mL] (R&D Systems).

5.3

Blood Collection and Lymphocyte Isolation
Healthy 5-7-week-old female athymic nude mice were euthanized by CO2

inhalation and blood was collected by ventricular puncture into heparin-containing tubes.
Blood from four mice was combined and diluted 1:1 with PBS. Blood was layered over 15
mL of Ficoll-Paque (Sigma-Aldrich) in a 50 mL conical tube and centrifuged at 500 x g
for 30 min with the brake off. Immediately afterwards, a Pasteur pipette was used to
carefully aspirate the mononuclear cell layer (located at the interface between the upper
plasma and lower Ficoll-Paque layers) and transfer it to a new 50 mL conical tube. Ten mL
of 0.8% ammonium chloride was mixed with the isolated cell layer to remove residual
erythroid components. The sample was then centrifuged for 10 min at 400 x g. The
supernatant was then decanted, and the cell pellet was resuspended in a small volume of
cell lysis buffer (1% NP-40, 25mM Tris-HCl pH 7.5, 100 mM NaCl, 5% Glycerol, 1x
Halt™ Protease Inhibitor Cocktail (Thermo Scientific)) for protein isolation.

5.4

BrdU Incorporation Assay
The bromodeoxyuridine (BrdU) incorporation assay was used to assess

proliferation of MDA-MB-231 and SUM149 human breast cancer cells. Cells (1x104
cells/well) were plated on 8-well Lab-tek™ chamber slides (Thermo Scientific) and
incubated for 24 h to allow adhering. Cells were then washed once gently with PBS and
serum starved for 72 h. Media was then changed to either basal media, positive control
media (basal media + 10% FBS), lung-CM or E-, L- or P-selectin depleted lung-CM for an
additional 24 h. Following incubation in the treatment conditions, cells were exposed to
BrdU (5 μg/mL; Amersham Cell Proliferation Labelling Reagent; GE Healthcare,
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Piscataway, NJ, USA) for 30 min to allow its incorporation into newly-synthesized DNA.
Cells were washed with PBS and fixed with 10% neutral-buffered formalin (Fisher
Scientific) for 5 min. Cell membranes were then permeabilized using 0.1% Triton X-100
(Sigma) in PBS for 10 min and subsequently treated with 2N HCl (Fisher Scientific) for
another 10 min to denature DNA. To minimize non-specific binding, slides were blocked
for 30 min in 5% bovine serum albumin (BSA) in 0.1% Triton X-100 in PBS. For detection,
anti-BrdU primary antibody (BD Biosciences) diluted 1:75 in 5% BSA/0.1% Triton X-100
in PBS was added and slides were incubated overnight at 4℃. Unbound primary antibody
was washed off with PBS and a FITC-conjugated anti-mouse IgG secondary antibody
(H+L made in horse; Vector Laboratories, Burlington, ON, Canada) diluted 1:100 in 5%
BSA + 0.1% Triton X-100 in PBS was added for 1 h at RT. Unbound secondary antibody
was washed off using PBS and the slides were then mounted with ProLong Gold Antifade
Mountant with DAPI (Invitrogen) and allowed to cure overnight in the dark at RT. Five
high powered fields of view (FOV) were taken per well and nuclei enumerated using
ImageJ. Results were expressed as the percentage of BrdU positive cells to total nuclei.

5.5

Transwell Migration Assay
The migration of MDA-MB-231 and SUM149 human breast cancer cells towards

lung-CM was assessed using transwell migration assays. Prior to the start of the assay,
Fluoroblok™ transwell inserts (24-well, 6.4 mm polyethylene terephthalate membrane, 8
𝜇m pore size; Corning Inc., Corning, NY, USA) were coated with 100 𝜇L of gelatin (6
𝜇g/well; Bioshop) and allowed to dry overnight in a sterile environment at RT.
Immediately prior to the assay, the gelatin was reconstituted with 100 𝜇L of control media
(DMEM:F12 + Mito+ + 0.1% BSA; Bioshop) and agitated for 90 min at RT. During the
reconstitution incubation, MDA-MB-231 or SUM149 cells were harvested, washed twice
with PBS and suspended at a concentration of 5 x 105 cells/mL. After reconstitution, excess
media from the top of the transwells was carefully removed and 100 𝜇L of cell suspension
was added in replacement. In the lower compartment of the transwell chamber, 600 𝜇L of
either negative basal media, 1:2 diluted lung-CM or 1:2 diluted lung-CM depleted of E-,
L- or P-selectin was added. Transwells were then incubated for 18 hours at 37°C and 5%
CO2 to allow migration. After 18 hours, transwell chambers were removed, fixed with 1%
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glutaraldehyde in PBS (Fisher Scientific) for 20 min. Transwell membranes were then
washed once with distilled water and a cotton swab was used to remove the non-migrated
cells from the inner portion of the membrane. Membranes were then carefully cut out,
placed on microscope slides and mounted using ProLong® Gold Antifade Mountant with
DAPI (Life Technologies). Five high powered FOV were captured for each membrane,
and a mean number of migrated cells/FOV was calculated using ImageJ software (NIH,
Bethesda, MD, USA).

5.6

Co-immunoprecipitation
To

assess

potential

interactions

between

selectins

and

CD44,

co-

immunoprecipitation was performed. Confluent 100 mm dishes of MDA-MB-231 cells
were washed three times with PBS and lysed with 500 𝜇L of lysis buffer (1% NP-40, 25mM
Tris-HCl pH 7.5, 100 mM NaCl, 5% Glycerol, 1x Halt™ Protease Inhibitor Cocktail
[Thermo Scientific]). Lysates were collected using cell scrapers and transferred to a 1.5
mL microfuge tube that was then placed on ice for 1 h. Following the incubation period,
lysates were centrifuged for 10 min at 13,000 g and 4℃. During this period, 20 𝜇L (0.6 𝜇g)
of Dynabeads were equilibrated in 200 𝜇L of wash buffer (25mM Tris-HCl pH 7.5, 100
mM NaCl, 5% Glycerol) and placed on a magnetic rack for 2 min to separate from solution.
Wash buffer was carefully removed and replaced with 500 𝜇L of MDA-MB-231 cell lysate
supernatant. The remaining pellet from the cell lysates was discarded.
Two micrograms of recombinant mouse E-selectin Fc chimera protein,
recombinant mouse L-selectin Fc chimera protein or recombinant mouse P-selectin Fc
chimera protein (R&D Systems) was added to each tube containing cell lysate/beads. Cell
lysate/beads

without

recombinant

protein

was

used

as

a

negative

control.

Lysate/bead/recombinant protein mixtures were placed on a rotator overnight at 4℃. The
following morning, tubes were placed on a magnetic rack to separate beads/bound proteins
from solution. The supernatant was then carefully removed, and remaining beads were
resuspended in wash buffer, washed and magnetically separated. The wash and separation
steps were repeated twice, beads were suspended in 30 𝜇L of Laemmli buffer, and boiled
for 5 min in a 100 ℃ water bath. After boiling, samples were placed on the magnetic rack
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for 2 min and the supernatant was transferred to a clean 1.5 ml microfuge tube for storage
at -20℃ until SDS-PAGE and immunoblotting were performed.

5.7

Immunoblotting
Cell lysates were quantified using the DC Protein Assay (Biorad, Hercules, CA).

Thirty micrograms of cell lysates or 30 𝜇L of immunoprecipitated samples were subjected
to separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto polyvinylidene difluoride membranes (PVDF; Millipore, Billerica,
MA). Membranes were blocked using 5% skim milk in Tris-buffered saline + 0.1% Tween20 (TBS-T; Sigma) for all western blots, unless otherwise indicated. Primary and
secondary antibody concentrations used are described in Table 2. Protein expression was
visualized using Clarity Max™ Western ECL Substrate (Bio-Rad) and normalized by
immunostaining for beta-actin as a loading control.

5.8

Phosphokinase Array
MDA-MB-231 human breast cancer cells were serum starved for 24 h and then

exposed to one of three conditions for 15 min: basal media, lung-CM or lung-CM depleted
of L-selectin. Immediately after treatment, cells were gently washed three times with cold
1x PBS and lysed with lysis buffer. Lysates protein concentrations were measured using
the BioRad DC protein assay (BioRad). The phospho-kinase array (Proteome Profiler™
Human Phospho-Kinase Array; R&D Systems) was carried out using 200 µg of each lysate
as per the manufacturer's guidelines. Using the kit-provided wash buffer, unbound proteins
were removed from membranes, and a cocktail of detection antibodies was applied. To
detect the amount of phosphorylated protein bound to each capture spot, streptavidin-HRP
and chemiluminescent agents were used to produce a signal. The signals were then
visualized using a ChemiDoc System and analyzed for densitometry using Image Lab™
Software (BioRad) (n=3 for each treatment condition). To validate the accuracy of the
phospho-kinase array and expand the number of treatment conditions being examined with
respect to identified proteins of interest, immunoblotting was performed. MDA-MB-231
cells were exposed to basal media, lung-CM (native or depleted of individual selectins) or
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Table 2. Details of primary and secondary antibodies used for immunoblotting
𝟏° or 2° Target
antibody Species
1°

Human

Target Protein

Clone

𝛽-actin

Polyclonal

Commercial Antibody Antibody
Source
Host
Conditions
1:5000
Sigma
Rabbit
O/N at 4℃
1:100
O/N at 4℃

1°

Human

CD44S

156-3C11

1°

Mouse

E-Selectin

96403

1°

Mouse

L-Selectin

95205

1°

Mouse

P-Selectin

Polyclonal

1°

Human

Ezrin/ Radixin/
Moesin

Polyclonal

Human

Phospho-Ezrin
(Thr567/
Radixin(Thr564)/
Moesin (Thr558)

1°

Polyclonal

Invitrogen
R&D
Systems
R&D
Systems
R&D
Systems
Cell
Signaling
Technology
Cell
Signaling
Technology
Cell
Signaling
Technology
Cell
Signaling
Technology

Mouse
Rat
Rat
Goat

1:500
O/N at 4℃
1:1000
O/N at 4℃
1:1000
O/N at 4℃

Rabbit

1:500
O/N at 4℃

Rabbit

1:500
O/N at 4℃

Rabbit

1:1000
O/N at 4℃

Rabbit

1:1000
O/N at 4℃

1°

Human

CREB

Monoclonal

1°

Human

Phospho-CREB
(Ser133)

Monoclonal

2°

Goat

Goat IgG

Polyclonal

Calbiochem

Rabbit

2°

Mouse

Mouse IgG

Polyclonal

Calbiochem

Goat

2°

Rabbit

Rabbit IgG

Polyclonal

Calbiochem

Goat

2°

Rat

Rat IgG

Polyclonal

Calbiochem

Goat

1:2000
(1 h @ RT)
1:2000
(1 h @ RT)
1:2000
(1 h @ RT)
1:2000
(1 h @ RT)
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recombinant protein (individual selectins diluted in basal media) conditions for 15 min as
described earlier and analyzed by immunoblotting for specific proteins of interest.

5.9

Statistical Analysis
A minimum of three biological replicates were performed for each experiment, with

three technical replicates within each experiment for transwell migration and BrdU
incorporation assays. All statistical analyses were performed using GraphPad Prism 6.0
(San Diego, CA, USA), and data are presented as mean ± standard error of the mean (SEM).
A one-way analysis of variance (ANOVA) was used to compare means between treatment
groups, followed by a Tukey’s post-hoc test to confirm significance. In some cases, a
Students t-test was used for pair-wise comparisons. P values less than 0.05 were deemed
statistically significant.
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6

RESULTS

6.1

E-, L-, and P-selectin are present in lung-CM
We have previously demonstrated that lung-CM generated from the lungs of

healthy female mice can be used as a model of the soluble lung microenvironment. Using
protein array analysis, we identified over 70 lung-derived proteins in lung-CM that are not
present in basal media25. In particular, E-, L- and P selectin were identified as proteins for
further investigation based on their previous association with metastasis and the fact that
they were known CD44 ligands88-90. Using ELISA, the presence and concentration of each
selectin protein was quantified in lung-CM relative to basal media. We observed that Eselectin (Figure 4A), L-selectin (Figure 4B) and P-selectin (Figure 4C) are present in
lung-CM at significantly higher concentrations than in basal media (p<0.05). Each selectin
could be successfully individually immunodepleted, resulting in lung-CM that had
significantly reduced levels of E-, L, or P-selectin compared to non-depleted lung-CM
(p<0.05). In the absence of a specific antibody, Dynabeads® Protein G alone had no
significant effect on immunodepletion of selectins. Analysis of positive controls (activated
endothelial cells) demonstrated the specificity of the ELISA for the selectins of interest.
We were also interested in trying to determine which selectin forms
(cleaved/soluble versus full-length) were present in lung-CM and attempted to characterize
this by immunoblot analysis of the immunoprecipitated fractions (Appendix 2). However,
lack of optimal antibodies for immunoblotting and the small difference in molecular weight
and antibody specificity made it very difficult to resolve two close bands in the case where
both forms might be potentially present, or to identify a band as one form with certainty
(in humans, it has been reported that the soluble forms of each selectin are 3-6 kDa smaller
than their full-length counterparts, as they are cleaved at a membrane proximal region such
that the transmembrane and cytoplasmic regions are removed68-70).
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Figure 4. E-, L-, and P-selectin are present in lung-conditioned media (CM) and can
be immunodepleted. Lung-CM generated from the lungs of healthy female nude mice was
assessed for the presence and concentration of (A) E-selectin, (B) L-selectin, and (C) Pselectin protein by ELISA, and immunodepletion (denoted by  symbol) was carried out
using specific respective antibodies coupled to Dynabeads® Protein G. Immunodepletion
controls included basal media, lung-CM exposed to Dynabeads Protein G only, and lungCM exposed to Dynabeads plus a nonspecific anti-mouse IgG antibody. Lysates of
lipopolysaccharide-stimulated mouse endothelial cells (EC) were used as an additional
positive control for E- and P-selectin. Data is presented as mean protein concentration +/SEM. (n=3). Analysis was carried out using a one-way ANOVA and Tukey’s post hoc test.
* = significantly different than basal media (p<0.05); # = significantly different than
respective non-depleted media (p<0.05); & = significantly different than lysis buffer
(p<0.05).
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6.2

Lung-derived selectins enhance breast cancer cell migration
Recent findings from our lab have demonstrated that cell migration of several breast

cancer cell lines including MDA-MB-231 and SUM149 is increased in response to lungCM relative to basal media25. To determine whether this effect is due in part to the presence
of E-selectin, L-selectin and/or P-selectin in lung-CM, a transwell migration assay was
used. MDA-MB-231 (Figure 5A) or SUM149 (Figure 5B) human breast cancer cells were
exposed to one of the following conditions for 18 hours: basal media, lung-CM, or lungCM depleted of E-selectin, L-selectin or P-selectin. Relative to the negative control basal
media, MDA-MB-231 and SUM149 human breast cancer cells demonstrated significantly
higher migration towards lung-CM (p<0.05). This increased migration towards lung-CM
could be abrogated in both cell lines when each selectin was individually immunodepleted
(p<0.05). Addition of specific recombinant mouse selectins to depleted lung-CM at a level
that restored selectin protein levels to those detected in the naive lung-CM rescued the promigratory effect of lung-CM to levels consistent with the non-depleted lung-CM (p>0.05).
Taken together, these results indicate that lung-derived E-, L-, and P-selectins can enhance
breast cancer cell migration.

6.3

Breast cancer cell proliferation is independent of lungderived selectins
Our group has also previously observed that lung-CM can not only increase

migration, but also influences the proliferation of human breast cancer cells25. To
determine whether selectins are contributing to the observed proliferative effect of lungCM, BrdU incorporation assays were used. MDA-MB-231 and SUM149 human breast
cancer cells were exposed to basal media, lung-CM, or lung-CM depleted of E-selectin, Lselectin or P-selectin for 24 h. Cells were then transiently exposed to BrdU and
incorporation was detected by immunofluorescence. Consistent with our previous study25,
we observed that a greater proportion of MDA-MB-231 (Figure 6A,B) and SUM149 cells
(Figure 6C,D) were BrdU-positive following exposure to lung-CM relative to basal media
(p<0.05). However, the proportion of BrdU-positive cells was unaffected by the individual
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Figure 5. Lung-derived selectins enhance breast cancer cell migration. (A) MDA-MB4
231 or (B) SUM149 human breast cancer cells (5 x 10 per well) were plated in triplicate
(n= 3) on top of gelatin-coated Corning® Fluroblok™ transwells (8-µm pore size) before
exposure to one of the following conditions: basal media; lung-CM; lung-CM depleted of
E-selectin; L-selectin or P-selectin (denoted by  symbol); or depleted lung-CM +
recombinant E-selectin, L-selectin or P-selectin (added at the concentration needed to
restore protein levels to that observed in native lung-CM). Cells were allowed to migrate
for 18 hours at 37°C and 5% CO2. Transwells were fixed, stained with DAPI, and five highpowered images were captured per transwell. Migrated cells were analyzed using ImageJ
software (NIH). Data is presented as mean fold-change in number of migrated cells relative
to basal media +/- SEM (n=3). Analysis was done with one-way ANOVA and Tukey’s post
hoc test. * = significantly different from basal media (p<0.05); # = significantly different
from non-depleted lung-CM (P<0.05).
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Figure 6. Breast cancer cell proliferation is independent of lung-derived selectins.
(A,B) MDA-MB-231 and (C,D) SUM149 human breast cancer cells were plated at a
density of 1x104 cells/well on 8-well chamber slides and serum starved for 72 hrs. Cells
were then exposed to basal media, lung-CM, and lung-CM depleted of E-selectin, Pselectin or L-selectin (denoted by  symbol) for an additional 24 h before assessing
proliferation based BrdU incorporation. Five high-powered images per well were captured
and used to enumerate the percentage of BrdU-positive cells using ImageJ software (NIH).
Data is presented as mean fold-change in BrdU relative to basal media +/- SEM (n=3). *=
significantly different from basal media (p<0.05).
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depletion of E-selectin, L-selectin and P-selectin from lung-CM (p>0.05), suggesting that
breast cancer cell proliferation is independent of lung-derived selectins.

6.4

Mouse selectins interact with human CD44 expressed by
MDA-MB-231 cells
To assess whether CD44S expressed by human breast cancer cells could interact

with murine selectins, we performed co-immunoprecipitation. The three selectin proteins
used were the soluble forms of mouse E-selectin-human IgG1 chimeric protein, mouse Lselectin-human IgG1 chimeric protein and mouse P-selectin-human IgG1 chimeric proteins
(R&D Systems). Since all three proteins contained a fused IgG region, it was theoretically
possible for them to interact directly with Dynabead® Protein G. We confirmed this by
incubating Dynabead® Protein G alone or in combination with one of the selectin proteins
overnight at 4℃. Samples were immunoprecipitated and analyzed by immunoblotting
(Figure 7) for the respective selectin protein using antibodies and conditions described in
Table 2.
A single band was observed in each lane containing recombinant protein that
immunoprecipitated with the Dynabead® Protein G (Figure 7A). This suggested that the
recombinant chimeric selectins could interact directly with the Dynabead® Protein G
without additional antibodies. We then went on to test whether CD44S interacted with the
murine selectin proteins. Cell lysates from MDA-MB-231 human breast cancer cells were
incubated overnight at 4℃ with Dynabead® Protein G alone or in combination with one of
the murine selectin-human IgG1 chimeric proteins. Immunoprecipitates were then assessed
by immunoblotting for human CD44S using antibodies and conditions described in Table
2. Bands corresponding to proteins of approximately 90 kDa in weight reacted with the
CD44S antibody and were observed in each of E-, L- and P-selectin immunoprecipitates
(Figure 7B). The protein size detected was consistent with the band observed from the
MDA-MB- 231 cell lysate input control. This suggests that murine E-, L-, and P-selectin
can interact with CD44S expressed by human breast cancer cells.
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Figure 7. Mouse selectins interact with human CD44S expressed by MDA-MB-231
cells. A) Dynabead® Protein G were incubated alone or with a murine E-, L- or P-selectinhuman IgG1 chimeric protein (R&D Systems) overnight at 4℃. Proteins potentially bound
to Dynabead® Protein G were isolated and analyzed by immunoblotting. Membranes were
blocked with 5% BSA in TTBS for 1 h at room temperature before overnight incubation at
4℃ with an anti-E-selectin (1:500), anti-L-selectin (1:1000) or anti-P-selectin (1:1000)
antibody diluted in 5% BSA in TTBS. Membranes were then washed with PBS and
incubated at room temperature for 1 h with an anti-rat IgG, anti-rat IgG or anti-goat IgG
secondary antibody (all diluted 1:2000 in 5% BSA in TTBS) for E-, L- and P-selectin,
respectively. Membranes were visualized by chemiluminescence and captured on a
ChemiDoc™ Imaging Systems. (n=3). B) MDA-MB-231 cell lysates were incubated
overnight at 4℃ with Dynabeads® Protein G alone or with 2𝝁g of murine E-, L- or Pselectin-human IgG1 chimeric protein. Immunoprecipitates were isolated and
immunoblotted. Membranes were blocked with 5% BSA in TTBS for 1 h at room
temperature, then incubated overnight at 4℃ with an anti-CD44S antibody (1:100 diluted
in 5% BSA in TTBS) and incubated at room temperature for 1 h with an anti-mouse IgG
secondary antibody (1:2000 dilution in 5% BSA in TTBS) the following morning.
Membranes were then visualized by chemiluminescence and captured on a ChemiDoc™
Imaging Systems. (n=3).
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6.5

Effect of lung-derived selectins and CD44 on migrationrelated signaling pathways
To determine whether the interaction between selectins and CD44S contributes to

the pro-migratory effect of selectins that we observed in our earlier experiments,
immunoblotting was used to investigate the effect of lung-derived selectins and/or CD44
on migration-related signaling pathways. The highly related ERM (ezrin, radixin, moesin)
proteins were of interest in examining because when phosphorylated they have been shown
to serve as linkers between CD44 receptors and the cytoskeleton91, 92. Through this role,
ERM proteins may facilitate pro-migratory signals93. Serum-starved MDA-MB-231 cells
were exposed for 15 min to native lung-CM or lung-CM that was depleted of E-, L- or Pselectin. Cellular response to lung-CM in the presence of a functional blocking antibody
against CD44S was also assessed. Cell lysates were collected and assessed by
immunoblotting for total ERM and phosphorylated ERM proteins (Figure 8). No
statistically significant changes in the ratio of ERM phosphorylation were observed among
treatments when examined together by one-way ANOVA. However, a direct comparison
of basal media and lung-CM treatments by t-test demonstrated that phosphorylation was
significantly increased in response to lung-CM (p<0.05). Taken together, this data suggests
that ERM phosphorylation is increased by proteins found in lung-CM but the effect is
independent of lung-derived selectins.
Given the complexity of intracellular signalling pathways and how they may mediate
migration and/ or proliferation, we used the Proteome Profiler™ Human Phospho-Kinase
Array (R&D Systems) to determine what additional proteins may be involved. This array
simultaneously profiles changes in the phosphorylation of 43 protein kinases and two
related total proteins. Lysates examined were from MDA-MB-231 cells that were treated
for 15 min with either basal media, lung-CM or lung-CM depleted of L-selectin. Relative
to the basal media treatment, the phosphorylation of a few proteins was significantly
increased by lung-CM treatment (Figure 9) (p<0.05). These proteins included extracellular
signal-regulated kinase 1 and 2 (ERK1/2), mitogen- and stress-activated protein kinases 1
and 2 (MSK1/2), cAMP response element binding protein (CREB) and tyrosine-protein
kinase (LYN). A significant effect of L-selectin immunodepletion from lung-CM relative

33

Figure 8. Effect of lung-conditioned media on ERM protein phosphorylation in
human breast cancer cells. MDA-MB-231 cells were cultured to 90% confluence and
then serum starved for 24 h. Cells were then exposed for 15 min to one of the following
conditions: basal media, lung CM, or lung CM depleted of E-selectin, P-selectin, L-selectin
(denoted by  symbol). Cellular response to lung-CM in the presence of a functional
blocking antibody against CD44S (CD44) was also assessed. Cells were lysed, protein
was quantified by Lowry assay and analyzed by immunoblotting. Membranes were
blocked with 5% BSA in TTBS for 1 h at room temperature before immunostaining
overnight at 4℃ with the primary antibody for ERM (1:1000 diluted in 5% BSA in TTBS)
or phosphorylated ERM (1:1000 diluted in 5% BSA in TTBS). The region of the membrane
at the molecular weight of actin was cut and probed with an anti-actin antibody (1:5000
diluted in 5% BSA in TTBS.) The following day, membranes were washed with PBS and
incubated with anti-rabbit secondary antibody (1:2000) for 1 hour at room temperature.
Bands were visualized using enhanced chemiluminence (ECL) and captured on a
ChemiDoc™ Imaging Systems. Quantification was carried out by densitometry using
ImageLab software. Data is presented as fold-change in ratio of total:phosphorylated ERM
protein relative to basal media condition. (n=3). *= significantly different from basal media
(p<0.05; t-test).
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Figure 9. Effect of lung conditioned media on protein phosphorylation in breast
cancer cells. MDA-MB-231 human breast cancer cells were incubated in basal media,
lung-CM or lung-CM depleted of L-selectin () for 15 minutes. Cells were then collected,
lysed and incubated with the Human Phospho-Kinase Array membrane (R&D systems) as
per the manufacturer’s instructions. The presence of phosphorylated proteins was detected
using biotinylated antibodies and visualized by chemiluminescence. A) Representative
arrays of the basal media, lung-CM and lung-CM depleted of L-selectin are presented.
Boxes outlined with dashed lines indicate internal positive controls. Boxes outlined with a
solid line are proteins of interest. Extracellular signal-regulated kinase 1 and 2 (ERK1/2),
mitogen- and stress-activated protein kinase 1 and 2 (MSK1/2), cAMP response elementbinding protein (CREB) and tyrosine-protein kinase Lyn are numbered 1 to 4, respectively.
B) Densitometry analysis was performed using Image Lab software (Bio-Rad) and oneway ANOVA with Tukey’s post-hoc statistical analysis was performed using GraphPad
Prism software. * = significantly different from basal media (p<0.05); # = significantly
different from lung-CM (p<0.05). Only kinases/proteins with significantly different
phosphorylation or expression between at least two treatments are shown.
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to non-depleted lung-CM (p<0.05) was only observed for the kinase LYN, although a nonsignificant trend (p>0.05) was also observed for CREB. Although the LYN effect could
not be validated by immunoblotting (data not shown), CREB was analyzed in greater detail
to determine whether lung-derived selectins might signal through this pathway. MDA-MB231 cells were exposed to non-depleted lung-CM or that which had been depleted of E-,
L-, or P-selectin. Cellular response to lung-CM in the presence of a functional blocking
antibody against CD44S was also assessed. Cell lysates were analyzed by immunoblotting
for total and phosphorylated CREB. We observed that while lung-CM treatment
significantly increased CREB protein phosphorylation relative to basal media (p<0.05)
(consistent with phosphokinase array results), immunodepletion of single selectins or
blocking with CD44 did not significantly affect CREB phosphorylation (p>0.05), although
a non-significant trend could be seen whereby CREB phosphorylation appears to be lower
in cells exposed to selectin-depleted lung-CM compared to native lung-CM, or cells
blocked by CD44 (Figure 10A). In an alternative approach, when MDA-MB-231 cells
were treated with recombinant E-, L- and P-selectin at concentrations 10x higher than those
observed in lung-CM, a slight but non-significant increase in CREB phosphorylation
relative to the basal media was observed only in the presence of E-selectin (p>0.05)
(Figure 10B).
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Figure 10. Lung-conditioned media enhances CREB phosphorylation. MDA-MB-231
cells were cultured to confluence and subjected to serum starvation for 24 hours. Following
this period, cells were exposed to treatment conditions for 15 min and then harvested, lysed
and their protein concentrations quantified by BioRad DC Protein Assay. 30 ug of protein
from each lysate was analyzed by immunoblotting. Membranes were blocked for 1 h at
room temperature with 5% milk in TTBS, followed by incubation with either P-CREB
(1:1000 dilution in 5% milk in TTBS) or CREB (1:1000 in 5% milk in TTBS) primary
antibody overnight at 4℃. The following morning, membranes were washed with TTBS
and then incubated with an anti-rabbit IgG secondary antibody for 1 hour before
visualization by chemiluminescence. Images were captured on a BioRad ChemiDoc
system and quantified by densitometry using ImageLab® software. One-way ANOVA and
Tukey’s post-hoc test were performed using GraphPad Prism software, and results are
presented as mean ± SEM (n=3) (A) Cells were treated with basal media, lung-conditioned
media (lung-CM) or lung-CM depleted of L-selectin, E-selectin, P-selectin. Cellular
response to lung-CM in the presence of a functional blocking antibody against CD44S
(CD44) was also assessed. (B) Cells were treated with basal media, lung-CM or
recombinant protein in basal media (mouse E-, L- or P-selectin) at concentrations ten-fold
higher than those detected in lung-CM. * = significantly different from basal media
(p<0.05)
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7

DISCUSSION
Breast cancer is the most commonly diagnosed cancer (with the exception of non-

melanoma skin cancers) and second leading cause of cancer-related deaths among
Canadian women94. Since the 1970s, considerable progress has been made in the clinical
management of the disease, with five-year survival rates having risen from 53% in the
1970s to almost 87% for women in 201695. This improvement can be primarily attributed
to improved early detection and the development of therapies that target the estrogen
receptor (e.g. tamoxifen) and the HER2 receptor (trastuzumab)96-98. Unfortunately, triplenegative breast cancer, the most aggressive subtype, does not express ER or HER2
receptors and no other effective targeted therapy exists99. In the metastatic setting, breast
cancer currently remains incurable.
The "seed and soil" hypothesis was originally proposed by Stephen Paget in 1889
and postulated that the formation of metastatic tumours at distant sites was related to not
only the intrinsic properties of the breast cancer cell (the “seed”) but also to factors found
in the organ microenvironment (the “soil”) that would allow the tumour cell to survive and
grow24. For three of the most common sites of breast cancer metastasis (lung, brain and
bone), studies conducted by Joan Massagué and colleagues elegantly demonstrated how
the genetic signature of breast cancer cells can contribute to determining organ-specific
metastasis26-28.
To study the influence of organ microenvironments common to breast cancer
metastasis, our group previously developed an ex vivo model that allowed the soluble
factors produced by a given tissue to be identified and their influence examined25. With
respect to the lung, we found that at least 70 unique soluble proteins are present, and that
these proteins include chemokines, cytokines, growth factors and extracellular matrix
components. Five of the identified proteins are known interactors of CD44, an extracellular
receptor that is a marker for aggressive breast cancer cells34. These proteins include basic
fibroblast growth factor100, osteopontin51, E-53, L-54 and P-selectin88. Our group has
demonstrated that basic fibroblast growth factor promotes the proliferation of breast cancer
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cells101, L-selectin promotes the migration of breast cancer cells and OPN enhances both
metastatic behaviours in vitro25.
This thesis focused on investigating the role and potential mechanisms of lungderived E-, L, and P-selectin in breast cancer metastatic behavior. We hypothesized that
lung-derived selectins promote breast cancer migration and/or growth via interactions with
CD44.

7.1

Summary of Experimental Findings

1. E-selectin, L-selectin and P-selectin are present in significant concentrations in lungCM and can be immunodepleted.
2. Each of the three selectin proteins promotes the in vitro migration of MDA-MB-231
and SUM-149 human breast cancer cells towards lung-CM.
3. Lung-CM promotes the in vitro proliferation of MDA-MB-231 and SUM-149 breast
cancer cells but its effect is independent of selectins.
4. CD44S expressed by MDA-MB-231 human breast cancer cells in vitro interacts with
soluble mouse E-, L- and P-selectin.
5. The phosphorylation of ezrin/radixin/moesin (ERM) proteins in MDA-MB-231
breast cancer cells is enhanced by exposure to lung-CM but is not significantly
affected by depletion of individual selectins.
6. Phosphorylation of CREB in MDA-MB-231 cells is significantly increased following
exposure to lung-CM relative to a basal media control but is not significantly
influenced by selectin depletion or addition.

7.2

Implications of Experimental Findings

The findings of this project support the hypothesis that lung-derived selectins have a
pro-metastatic role in breast cancer, specifically through migration. Our group was the first
to examine the response of breast cancer cells to selectins in the context of the lung
microenvironment.
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7.2.1

Forms of Selectins Found in Lung-Conditioned Media

In the literature, the in vivo presence and expression of selectins in the lung has been
well-established25, 102, 103. Using ELISA, we quantified the amount of each selectin in lungconditioned media. While we cannot confirm whether the concentrations observed are
equal to those observed in the native lung microenvironment, we can at least appreciate
their presence, the relative amounts of each selectin family member, and begin to
understand the role they may have in breast cancer metastatic behavior.
Due to the nature of our lung-CM model and the need for mechanical dissociation of
mouse lungs, the possibility exists that some of each selectin detected by ELISA was of
the full-length form. Full-length forms of the protein could have been released from the
cell membrane if mechanical dissociation of the lungs damaged the cells. We attempted to
determine the presence and relative amount of full-length versus soluble forms of each
selectin by immunoprecipitation and subsequent immunoblotting. In humans, the soluble
form of each selectin is approximately 3-6 kDa smaller that its full-length counterpart, and
the soluble forms of the protein are generated by cleavage at a membrane proximal site
such that the transmembrane and cytoplasmic regions are removed68-70. Unfortunately, a
lack of optimal antibodies and the small difference in molecular weights between the two
forms of each selectin made it difficult to resolve and identify which species were present
in our lung-CM. However, studies suggest that both soluble and full-length forms of each
protein (E-selectin104,
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, L-selectin73 and P-selectin106) interact with the same

receptors/binding partners. Therefore, both forms should theoretically exert the same
functional influence on breast cancer cells in our ex vivo model.

7.2.2

Lung-derived Selectins are Important for Breast Cancer Migration
but not Growth

Next we assessed the functional influence of lung-derived selectins on breast cancer
cells and whether it occurs through CD44S, a cell surface receptor that has a wellcharacterized role in regulating the proliferation, migration and invasion of breast cancer
cells107. Selectins present in lung-CM were observed to play significant roles in migration
of breast cancer cells but did not influence proliferation, as assessed by transwell migration
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and BrdU incorporation assays, respectively. A study conducted by Kumar and colleagues
was among the first to demonstrate that soluble E-selectin had a chemotactic effect on
immune cells72. This was followed by a recently published study in which soluble Eselectin was shown to promote the migration of MDA-MB-231 human breast cancer cells
potentially through interactions with CD44108, which supports our findings. With respect
to proliferation, there is no direct evidence implicating E-selectin in the proliferation of
cancer cells in vitro. However, soluble E-selectin has previously been shown to mediate
angiogenesis in vitro and in the context of breast cancer, E-selectin deficiency has reduced
the number of lung metastatic foci86. It is difficult to extrapolate whether changes in the
number of metastatic foci observed were related to migration and/or proliferation, as no
comparison in the size of metastatic foci was made between wild-type and E-selectin
deficient mice.
In comparison to E-selectin, relatively little is known about L-selectin and its influence
in breast cancer. In the context of breast cancer, previous work by our laboratory
demonstrated that the migration of MDA-MB-231 human breast cancer cells towards lungCM was mediated in part by L-selectin25. The work of this thesis added to our previous
findings by demonstrating that the migration of MDA-MB-231 breast cancer cells
abrogated by depletion of L-selectin from lung-CM could be rescued through addition of
recombinant L-selectin, and by replicating these experiments with all three selectins and in
a second breast cancer cell line, SUM149.
There are many studies that have used animal models of cancer to examine the role of
P-selectin in metastasis. One of these used a spontaneous model of breast cancer metastasis
and interestingly observed that although P-selectin deficiency in mice did not decrease the
incidence of lung metastasis, the overall metastatic burden in the lung was significantly
higher than that of their wild-type counterparts86. They suggested an impaired ability of Pselectin deficient mice in recruiting neutrophils and monocytes was driving this
observation109. However, in other cancers, such as melanoma and colon carcinoma,
opposing results were observed. In an experimental model of melanoma metastasis in
which cancer cells were intravenously administered into mice, the number of lung
metastases in P-selectin deficient mice was less than half of that observed in wild-type
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mice110. Similarly, in a spontaneous metastasis model of colon carcinoma, only 11% of Pselectin deficient mice had any histological signs of tumour cells or microscopic nodules
in the lungs. In comparison, signs of metastasis were observed in 89% of wild-type mice
injected with tumour cells103.
At the cellular level, published evidence has suggested a role for P-selectin in cancer
cell proliferation, with subcutaneously implanted colon carcinoma cells having
significantly lower primary tumour growth in P-selectin deficient mice versus in wildtype103. To the best of our knowledge, no previous studies have investigated the influence
of P-selectin (lung-derived or otherwise) on migration or proliferation in the context of
breast cancer, although a previous study by Morbidelli and colleagues demonstrated that
soluble P-selectin could promote endothelial cell migration in vitro111.
While we did not explore the effects of depleting multiple selectins from lung-CM, we
did observe that depletion of each selectin individually significantly affected migration of
breast cancer cells. It is possible that the selectins may either function through interactions
with different receptors at the cell surface or by activating different intracellular
mechanisms. This idea is supported by a study on lung metastasis of adenocarcinoma in
mice. Borsig and colleagues observed that mice deficient in P-selectin and L-selectin had
a significantly lower burden of lung metastasis than wild-type mice or those deficient in
only one of the selectins (L- or P-selectin)87. How selectins function in the context of
metastasis, whether it is through a single receptor or mutual downstream mechanisms, has
not been well examined. Furthermore, it is still not clear whether each selectin functions
differently/synergistically in migration of breast cancer cells, and/or whether E-,L- and Pselectin may be redundant/compensatory for each other.

7.2.3

Interaction of Lung-Derived Selectins with CD44

The receptor that we were most interested in examining was CD44, as previous
evidence has not only supported a role for the receptor in cell migration/invasion57, but also
demonstrated that it can interact with all three selectins53-55. An interaction of E-selectin
with CD44 expressed by LS174T colon carcinoma cells was originally hypothesized based
on CD44 immunoreactivity with the HECA-452 antibody, which detects sialofucosylated
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oligosaccharides (a group that E-selectin binds to)112. For P- and L-selectin, studies
demonstrated an interaction with CD44 by blot rolling assays88. However, detection of a
direct interaction by co-immunoprecipitation of selectins with CD44 expressed by breast
cancer cells has only been reported for E-selectin113. We therefore investigated this further
using recombinant mouse soluble selectin-human IgG chimera proteins, which are capable
of directly interacting with Dynabead® Protein G. This allowed us to avoid potential issues
of immunoprecipitating CD44 or selectins using antibodies that target the ectodomains
through which they may interact, since the IgG region that interacts with the Dynabead®
Protein G is located near the C-terminus of the chimera, far from the ectodomains. We
tested this using soluble mouse selectins, as these were the forms that we hypothesized
were found in our lung-CM model.
The interaction of CD44 with mouse selectins that we observed was facilitated by the
high degree of homology shared between human and mouse selectins. There is on average,
72% homology in the lectin region of selectins between mouse and human63. Whether
and/or how this interaction might activate CD44-associated pro-migratory signaling
pathways was examined in further studies.

7.2.4

Potential Mechanisms Underlying the Pro-Migratory Effect of
Lung-Derived Selectins

Previous studies have suggested ERM (ezrin/radixin/moesin) proteins are involved in
promoting migration, potentially through their roles as crosslinkers between CD44 and the
underlying actin cytoskeleton114,
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. For example, the N-terminal domain of

phosphorylated ezrin binds to the cytoplasmic tail of CD44 and the C-terminal domain of
ezrin binds to actin. This function is only possible when the ERM proteins are
phosphorylated at key threonine residues91. In their respective unphosphorylated states, the
N- and C-terminal domains of ERM proteins self-associate and make the protein
conformationally inaccessible to binding partners116. Based on these previous studies, we
therefore examined whether lung-derived selectins affected the phosphorylation of the
ERM proteins.
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In our results, we observed that exposure of human breast cancer cells to lung-CM
increased ERM phosphorylation relative to the basal media negative control. However, no
significant differences in phosphorylation were observed between control, lung-CM, lungCM depleted of a single selectin type or when cells were pre-treated with a neutralizing
antibody for CD44. This suggested that the effect of selectins on CD44-associated
migration may not be through induced changes in ERM phosphorylation. Rather, selectin
interactions with CD44 may affect CD44-pERM interaction. A recent study by Donatello
and colleagues observed that there were no differences in the ratio of phosphorylated to
total ERM proteins between migrating and non-migrating breast cancer cells117. However,
by co-immunoprecipitation they did observe greater association of CD44 with pERM in
migrating cells than non-migrating cells. This is something that should be further explored
in future studies.
In addition to our investigation of ERM phosphorylation, we next sought to identify
alternative intracellular mechanisms by which lung-derived selectins may affect breast
cancer cell migration. This was done using a human phospho-kinase array. When
comparing the effects of basal media, lung-CM and lung-CM depleted of L-selectin on
human breast cancer cells, we identified CREB as a potential protein of interest because it
had the greatest fold change vs. control in its phosphorylation response to lung-CM. Upon
further analysis, CREB phosphorylation was validated by immunoblotting to be
significantly elevated in breast cancer cells treated with lung-CM and slightly but nonsignificantly reduced upon depletion of a single selectin from lung-CM. Similarly,
treatment of these cells with recombinant selectin proteins led to a small but non-significant
increase in CREB phosphorylation relative to the basal media control, leading to the
conclusion that we were unable to demonstrate a role for selectins in CREB
phosphorylation. Although previous studies have associated CREB with migration of
breast cancer cells and hepatocellular carcinoma cells, the observed effect may be through
other soluble proteins found in lung-CM 118, 119.
In our phospho-kinase array, another kinase, tyrosine kinase Lyn, was observed to have
increased phosphorylation in breast cancer cells exposed to lung-CM relative to those
exposed to basal media. Interestingly, depletion of L-selectin from lung-CM significantly
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reduced phosphorylation of Lyn. In the context of human colon cancer, Lyn has been
implicated as a mediator of cell migration downstream of CD44. Researchers observed that
CD44 interacted with Lyn and that siRNA knockdown of CD44 in colon cancer cells was
associated with lower cell migration and Lyn expression relative to the parental cell line120.
To our knowledge, the role of Lyn kinase downstream of CD44 in breast cancer has not
been investigated and it is an avenue for our group to investigate further in the future.

8

Limitations of the Study
A considerable portion of our study involved an ex vivo model system of the soluble

lung microenvironment. While it allowed us to easily explore the effects of lung-derived
selectins on breast cancer cells, there are limitations that should be acknowledged. The first
is that by examining the effects of soluble lung-derived factors on breast cancer cells in
isolation, we are ignoring the important contribution that insoluble lung ECM factors and
other cells of the lung may have on the cancer cells. Studies of small cell lung cancer have
shown that interaction of the cells with ECM proteins such as fibronectin, laminin and
collagen IV can both enhance tumorigenicity and confer resistance to chemotherapeutic
agents121. With respect to the cell-cell interactions, a 2011 study by Qian and colleagues
demonstrated that the interactions between monocytes and breast cancer cells were
involved in lung metastasis. They noted that breast cancer cells secreted a chemokine
capable of activating monocytes that would go on to support cancer cell transmigration122.
The second limitation of our lung-CM model is that it involves lungs harvested from
athymic nude mice. Athymic nude mice lack T-cells and lack cell-mediated immunity. This
impairs their ability to mount robust immune responses, something that is increasingly
recognized as an important factor in cancer development and progression. For example,
the number of CD8+ T-cells present in primary breast tumours has been associated with
better patient survival123. Similarly, a study on non-small-cell lung cancer demonstrated
that increased infiltration of CD4+ and CD8+ T-cells in lung tumours was associated with
better patient prognosis as well124. In future investigations, models that take into
consideration the potential influence of the immune system, cell-ECM and cell-cell
interactions should be used.
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The third limitation of the study is the assumption that human breast cancer cells can
interact with murine lung soluble factors. Generally, it should not be a concern because the
protein-coding regions of the mouse and human genomes are 85% identical on average125.
A previous study has also shown that of 4,000 genes examined between humans and mice,
there are less than ten gene products which exist in one species, but no closely-related form
exists in the other. Nonetheless, we must express caution in our interpretation of relevance
to human disease, as exceptions have been shown in the literature where human proteins
cannot interact with the mouse equivalents of their known binding partners126.
It is also important to be cognizant of our use of immortalized human breast cancer cell
lines rather than primary human breast cancer cells. While the cell lines we used are well
characterized in the literature, they may not fully recapitulate the inherent heterogeneity
that is seen in the breast cancer patient populations. Researchers previously observed
differences in the expression of genes related to metabolism and cell communication
between primary metastatic breast cancer cells and established breast cancer cell lines127.
To try to minimize concerns of discrepancies, our cells are maintained at low passage
numbers and routinely authenticated.
Finally, protein phosphorylation, especially that of ERM, is a dose- and time-dependent
event128. While we were unable to observe a significant change in ERM phosphorylation
following cell treatment with different depleted lung-CM, the possibility exists that a
noticeable effect may occur, but outside of the time window we had examined.

9

Future Directions
While this study contributes to our understanding of selectins and the role they may

play in breast cancer metastasis to the lung, some questions remain unanswered, in
particular related to the potential intracellular mechanisms by which selectins exert their
influence on breast cancer cells.
As mentioned above, binding of CD44 by selectins may not necessarily increase ERM
protein phosphorylation but could alternatively affect the interaction between p-ERM and
CD44. By immunofluorescence, we should examine whether ERM proteins and CD44
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colocalize after cell stimulation with recombinant selectin proteins. To determine if any
colocalization observed is a result of direct protein interactions, co-immunoprecipitation
of phosphorylated ERM proteins with CD44 could be examined. These findings could
allow for more definitive conclusions to be made regarding whether the pro-migratory roles
of selectins occur via CD44 and ERM.
Next, we should examine other proteins of interest identified by the phospho-kinase
array, and in particular, tyrosine kinase Lyn, which has previously been shown to function
downstream of CD44120. In our experiments with the phospho-kinase array, we observed
greater phosphorylation of Lyn in response to lung-CM treatment relative to control, and
the extent of phosphorylation to lung-CM was partially abrogated by L-selectin depletion.
In future experiments, improved Lyn antibodies for immunoblotting should be used to
examine the effects of depleting each selectin from lung-CM or blocking CD44 on Lyn
phosphorylation in breast cancer cells.
Another idea to explore is whether there is synergy between selectins when
influencing breast cancer cells. While we have shown the effects of removing selectins
individually from lung-CM on breast cancer cells, it is unknown as to whether the influence
on migration would be strengthened further if two or more selectins were depleted. In vivo
evidence from experimental models of lung metastasis of colon adenocarcinoma suggests
that L- and P-selectin can function synergistically to enhance metastasis87. In addition to
studies that examine the effect of depleting lung-CM of multiple selectins, we should
explore effects of inhibiting selectins with small molecules. Rivipansel (GMI-1070) is a
pan-selectin inhibitor that is currently in a phase 3 clinical trial for the treatment of vasoocclusive crises secondary to sickle cell disease129. Although it is not yet commercially
available, this drug has been shown to have excellent safety and tolerability in humans130.
Testing of this drug in our ex vivo model of the lung microenvironment could provide
valuable preclinical data for Rivipansel’s therapeutic value in the treatment of breast cancer
metastasis to the lung.
Although the lung-CM model can be used to provide valuable insight about lungderived soluble factors, it does not consider cell to cell and cell to insoluble ECM protein
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interactions. This can be addressed using a 3D ex vivo model of the lung microenvironment.
The pulmonary metastasis assay (PuMA) is an ex vivo system in which mouse lungs are
cut into thin slices (1-2 mm thick) and maintained in culture62,

101, 131

. Our lab has

previously demonstrated that if animals are intravenously injected with breast cancer cells
15 min prior to euthanasia, this is enough time for tumour cells to be seeded in the lung101.
By then examining lung slices at different time-points, we can see cancer progression from
the single cell to micrometastatic to macrometastatic stages. Using the PuMA, we could
compare tumour progression between breast cancer cells that do or do not express CD44
in conjunction with comparisons of this in wild-type and selectin-knockout (single or
multiple selectin deficiency) mice. These experiments could further our understanding of
the importance of CD44 interactions with lung-derived selectins in breast cancer
metastasis.
Finally, since we were unable to identify which forms of each selectin (soluble and/or
full-length) were present in our lung-CM, we should further examine this using alternative
approaches. Two different primary antibodies (from different host species) for each
selectin should be used, one for immunoprecipitation and the other for immunoblotting. By
using a different primary antibody from different host species such that the secondary
antibody only interacts with the antibody used for immunoblotting and not coimmunoprecipitation, we may avoid the interference on our immunoblots that residual coimmunoprecipitation antibody left in our samples may cause.
For E-selectin and P-selectin, the molecular weight at which selectins in lung-CM are
detected should be compared to samples from LPS-activated mouse endothelial cell
supernatant (for the soluble form) and their cell lysates (membrane bound form), as they
are appropriate positive controls. For L-selectin isolated from lung-CM, the molecular
weight observed should be compared with the supernatant of LPS-stimulated neutrophils
and lysates of untreated neutrophils isolated from mice132. L-selectin is constitutively
expressed by neutrophils but LPS-stimulation causes L-selectin cleavage from the cell
surface into its soluble form133.
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It has long been known that breast cancer displays a pattern of preferential metastasis,
and one common site to which it spreads is the lung. Since breast cancer metastasis to the
lung is a major contributor to the disease-related mortality, it is important that we elucidate
why cancer cells preferentially metastasize to the lungs and how we can prevent/treat this
cancer progression. Using lung-CM as an ex vivo model system, we tested the hypothesis
that lung-derived selectins promote breast cancer migration and/or growth via interactions
with CD44. Using our model in conjunction with in vitro transwell migration and BrdU
incorporation assays, we observed that all three lung-derived selectins promoted the
migration of breast cancer cells but were not involved in breast cancer cell proliferation.
By immunoprecipitation, we also demonstrated that CD44 expressed by MDA-MB-231
human breast cancer cells interacts with selectins and that these interactions may mediate
the pro-migratory effects observed. Although we were unable to define a pathway by which
the CD44-selectin interactions may be propagating the signal intracellularly, we did
identify potential targets of interest and they remain under investigation. Nonetheless, the
findings of this thesis support the idea of the lung microenvironment playing a role in breast
cancer metastasis. In accordance with the “seed and soil” theory, targeting the lung
microenvironment and interfering with factors that would otherwise enhance the metastatic
behaviour of breast cancer cells could be a potential therapeutic strategy. This approach
could be feasible for treating lung metastases of breast cancer, as it should be easier to
target the constant composition of the lung between patients than the highly heterogeneous
population of cells that make up breast cancer.
In conclusion, our investigation has provided the foundation for the involvement of
selectins in lung metastasis of breast cancer. Taken together with further studies, this could
contribute to improved treatment of breast cancer in the metastatic setting and help reduce
the burden of this disease on humanity.
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Appendices
Appendix 1: Approved Animal Use Protocol
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Appendix 2: Immunoblotting analysis of immunoprecipitated selectins from lung-CM.
Lysates from normal and activated mouse pulmonary vein endothelial cells (EC) were used
as positive controls for E-selectin and P-selectin. Lysates from primary mouse leukocytes
were used as a positive control for L-selectin. (A) Immunoblot analysis of E-selectin
immunoprecipitated samples from lung-CM revealed 2 bands: one at 75 kDa and another
at approximately 65 kDa. These two bands were not observed in the IgG control. For the
positive control of mouse pulmonary vein endothelial cells (MPVEC), both the untreated
and those activated by lipopolysaccharide (LPS) treatment displayed numerous bands
when subject to immunoblotting. A specific molecular size for E-selectin could therefore
not be inferred from the MPVEC. (B) Immunoblot analysis of L-selectin
immunoprecipitated from lung-CM revealed non-specific binding and no differences in
banding pattern relative to the IgG control. A positive control of leukocytes isolated from
the blood of female nude athymic mice revealed a band at approximately 45 kDa in size.
This region is at the same molecular size as IgG heavy chains (~50 kDa) that were
otherwise strongly stained for in immunoprecipitated samples, suggesting a masking of
this band in the immunoprecipitated samples. (C) Similarly, immunoblot analysis of Pselectin immunoprecipitated from lung-CM revealed non-specific binding and no
differences in banding pattern relative to the IgG control. However, a set of two bands at
approximately 45 kDa were observed in immunoblots of untreated and activated
endothelial cell lysates.
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